• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.01% Nasdaq Up0.26%

    More On NEU.AX



    News & Info


    Analyst Coverage


    • Major Holders
    • Insider Transactions
    • Insider Roster


    Neuren Pharmaceuticals Limited (NEU.AX)

    0.09 Down 0.00(1.15%) Nov 25
    ProfileGet Profile for:
    Neuren Pharmaceuticals Limited
    697 Burke Road
    Suite 501
    Camberwell, VIC 3124
    Australia - Map
    Phone: 61 3 9092 0480
    Website: http://www.neurenpharma.com

    Index Membership:N/A
    Full Time Employees:N/A

    Business Summary 

    Neuren Pharmaceuticals Limited, a biopharmaceutical company, focuses on the development of therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Its products in development include Trofinetide, which is in Phase II clinical trials for use in the treatment of Rett syndrome, Fragile X syndrome, moderate to severe traumatic brain injury, and concussion; and NNZ-2591, a synthetic analogue of a naturally occurring neuropeptide that is in preclinical development for the treatment of various neurodegenerative disorders. The company has collaborative relationships with the US Army Medical Research & Materiel Command; and the Walter Reed Army Institute of Research. Neuren Pharmaceuticals Limited is based in Camberwell, Australia.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Neuren Pharmaceuticals Limited

    Key Executives 
    Dr. Richard Spencer Treagus BScMed, MBChB, MPharmMed, MBA,
    Exec. Chairman
    Mr. Lawrence Glass BA (Biology),
    Chief Science Officer and Exec. Director
    Mr. Jonathan Charles Pilcher BSc (Hons), ACA,
    Chief Financial Officer and Company Sec.
    Dr. Joseph Horrigan ,
    VP of Clinical Devel. & Medical Affairs
    Dr. Nancy E. Jones Ph.D.,
    Sr. Director of Clinical Devel. and Medical Affairs
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in AUD.